13. Multiple sclerosis/Neuromyelitis optica
3,050 clinical trials,   2,147 drugs   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00228228 (ClinicalTrials.gov) | May 2002 | 26/9/2005 | TCV -01-002: T-Cell Vaccination in the Treatment of Probable Multiple Sclerosis | T-Cell Vaccination in the Treatment of Probable Multiple Sclerosis | Multiple Sclerosis | Biological: T cell vaccination | Sheba Medical Center | NULL | Recruiting | 15 Years | 50 Years | Both | 80 | Phase 3 | Israel |
2 | NCT00220428 (ClinicalTrials.gov) | July 1998 | 14/9/2005 | T-Cell Vaccination in Multiple Sclerosis (MS) | The Effect of T-Cell Vaccination in Multiple Sclerosis - Phase I/II Safety and Efficacy Trial | Multiple Sclerosis | Biological: T-Cell Vaccination | Sheba Medical Center | NULL | Recruiting | 16 Years | 60 Years | Both | 20 | Phase 1;Phase 2 | Israel |